30 closest matches · ranked by relevance
KIF5B-RET-Positive Adenocarcinoma of the Lung
Primary: Objective Response Rate (ORR) — 16.0 percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 0 Participants
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
Carcinoma, Non-small Cell
Primary: Progression-Free Survival (PFS) at Month 4: Cohort A — 76.9 percentage of participants
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC V7
Primary: Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA) — 9 percentage of participants
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Lung Cancer
Primary: Progression-Free Survival — 4.1; 3.9 months
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
FGFR1 Gene Amplification · FGFR1 Gene Mutation · FGFR2 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 7 percentage of participants
Non-squamous, Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR): Based on Charted/Physician-reported Disease Response — 37.5; 76.3; 43.8; 77.8 percentage of patients
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Non Small Cell Lung Cancer
Primary: Progression Free Survival at 3 Months — 50.4 percentage of participants
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Lung Neoplasms
Primary: Progression-free Survival — 12.78; 11.17 Months — p=0.0891
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants